Pregabalin Capsule
Product Images NDC 82804-247

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 82804-247). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-247-90 (Image 01)

Label for Pregabalin 100 mg capsules, 90 count, relabeled by Proficient Rx LP. The capsules contain 100 mg of pregabalin each and are white to off-white granular powder in size 3 hard gelatin capsules, with a white opaque body imprinted "PGBN" and light blue opaque cap imprinted "100" with black ink. Manufactured by MSN Laboratories Private Limited, India. Storage recommended at 25°C (77°F). The NDC number shown is 82804-247-90 and the product is classified as a C-V controlled substance for prescription use.*

FDA Label Image

Equation (Pregabain Gault Equation)

A pharmacokinetic formula panel showing the calculation for creatinine clearance (CLCr), using age, weight, serum creatinine, and a factor adjustment for female patients. The formula helps in assessing kidney function relevant to drug dosing.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. Four lines compare effects of Pregabalin at doses 25 mg, 100 mg, and 200 mg three times a day, plus placebo. The y-axis shows percent of patients improved, and the x-axis shows percent pain improvement from baseline from 0 to 100.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A Kaplan-Meier curve chart illustrating the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day (dashed line) to placebo (dotted line). The x-axis represents percent improvement in pain, and the y-axis represents the percent of patients improved, showing higher improvement with Pregabalin compared to placebo.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A Kaplan-Meier survival curve chart showing percent of patients improved versus percent improvement in pain from baseline. The graph compares four curves: Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and placebo. The vertical axis is percent of patients improved (0 to 100%), and the horizontal axis is percent improvement in pain (0 to 100%). Each curve declines as improvement percentage increases, illustrating differential patient improvement rates by dose and placebo.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A Kaplan-Meier curve graph depicting the percent of patients improved by percent improvement in pain from baseline for Pregabalin capsules. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The vertical axis shows the percent of patients improved (0-100%), and the horizontal axis shows percent improvement in pain from baseline (0-100%).*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

Scatter plot graph showing the percent of patients improved plotted against percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line). The vertical axis represents percent of patients improved, and the horizontal axis shows percent improvement in pain from baseline with intervals marked at greater than 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 percent.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

Bar chart showing responder rates (%) from two clinical studies (E1 and E3) comparing placebo and various doses of Pregabalin capsules. The chart displays responder rates increasing with higher dosages, with study E1 doses given BID (twice daily) and study E3 doses at 600 mg either BID or TID (three times daily). Sample sizes (N) vary across groups.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

Line graph showing seizure reduction as median percentage change from baseline versus dose in mg/day for different Stukly regimens (E1BID, E2BID, E3BID, E3TID). Data points are connected by dotted lines, with p-values indicating statistical significance of changes. The x-axis represents dose from 0 to 600 mg/day, and the y-axis shows seizure reduction up to 60%.*

FDA Label Image

Pregabalin-figure-08 (Pregabalin Figure 08)

A vertical bar chart displaying responder rates (%) for three groups: Placebo, 2.5 mg/kg/day, and 10 mg/kg/day. The placebo group shows a responder rate of 22.6%, 2.5 mg/kg/day group 29.1%, and 10 mg/kg/day group 40.6%. Sample sizes for each group are also indicated below the x-axis (Placebo: 93, 2.5 mg/kg/day: 103, 10 mg/kg/day: 96).*

FDA Label Image

Pregabalin-figure-09 (Pregabalin Figure 09)

A line graph showing multiple curves depicting changes over time or percentage values, with a vertical axis labeled from 0 to 100. The graph uses different line styles (solid, dashed, dotted) to differentiate data series, but specific variables and exact values are not labeled.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve graph showing the estimated percentage of subjects without LTR (loss to response) over 180 days. The x-axis represents days, and the y-axis shows the estimated percentage of subjects without LTR, ranging from 0% to 100%. Two lines are displayed: a solid line for Pregabalin and a dashed line for Placebo, illustrating their comparative subject retention without LTR over time.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percent of subjects improved versus percent improved from baseline to week 12 BOCF for Pregabalin versus Placebo. The y-axis shows the percent of subjects improved, while the x-axis shows percent improved from baseline to week 12. Pregabalin is represented by a solid line, and Placebo by a dotted line, showing higher improvement percentages for Pregabalin.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A line graph comparing the percent of subjects improved on the y-axis against percent improved from baseline to week 16 BOCF on the x-axis, showing two lines: one solid line representing Pregabalin and one dotted line representing Placebo. The graph illustrates a higher percentage of subjects improved with Pregabalin compared to Placebo throughout the range.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure of pregabalin, illustrating its molecular layout including the amino group, carboxyl group, and branched side chains.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.